Eugene Williams - 07 Jul 2022 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Reporting relationship: Chairman and CEO, Director
Issuer ticker: PMN
Reported as of: 07 Jul 2022
Net transaction value: $0
SEC form: 3
Accepted by SEC: 07 Jul 2022, 19:29:04 UTC
Next SEC filing: 12 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Jason L. Langford, Attorney-in-Fact for Eugene Williams

Key filing fact

Eugene Williams filed Form 3 for ProMIS Neurosciences Inc. (PMN) on 07 Jul 2022.

Key facts

This page summarizes Eugene Williams's Form 3 filing for ProMIS Neurosciences Inc. (PMN).
0 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 07 Jul 2022, 19:29.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PMN holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 153,930
Date: 07 Jul 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMN holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 78,822
Exercise price: $2.43
Footnotes: F1, F2

PMN holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 36,988
Exercise price: $3.90
Footnotes: F1, F3

PMN holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 16,667
Exercise price: $28.20
Footnotes: F1, F4

PMN holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 50,000
Exercise price: $8.40
Footnotes: F1, F5

PMN holding Derivative

Warrants (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 833
Exercise price: $18.00
Footnotes: F1

PMN holding Derivative

Warrants (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 556
Exercise price: $28.80
Footnotes: F1

PMN holding Derivative

Warrants (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 1,927
Exercise price: $28.80
Footnotes: F1

PMN holding Derivative

Warrants (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 1,111
Exercise price: $21.00
Footnotes: F1

PMN holding Derivative

Warrants (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Jul 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 3,472
Exercise price: $12.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Conversion or exercise price is in Canadian dollars.

Footnote F2

The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on July 6, 2015.

Footnote F3

The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on July 31, 2015.

Footnote F4

The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on March 29, 2018.

Footnote F5

The option agreement provides that the options become exercisable in 48 equal monthly installments beginning one month after the grant. The option was granted on February 10, 2022.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .